Meeting
2013 ASCO Annual Meeting
Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab (CET) for refractory recurrent/metastatic squamous cancer of head and neck (R/M-SCCHN).
Authors
Bonnie S. Glisson
The University of Texas MD Anderson Cancer Center, Houston, TX
Bonnie S. Glisson , Jennifer Tseng , Shanthi Marur , Dong M Shin , Barbara A. Murphy , Ezra E.W. Cohen , Christopher Y. Thomas , Richard Willey , Jan Cosaert , William Nassib William , Nusrat Harun , J. Jack Lee , Robert I. Haddad
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
NCT00617734
Citation
J Clin Oncol 31, 2013 (suppl; abstr 6030)
DOI
10.1200/jco.2013.31.15_suppl.6030
Abstract #
6030
Poster Bd #
19
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study.
First Author: Christine H. Chung
Poster
2018 ASCO Annual Meeting
RM-1929 photo-immunotherapy in patients with recurrent head and neck cancer: Results of a multicenter phase 2a open-label clinical trial.
First Author: Ann M. Gillenwater
Poster
2016 ASCO Annual Meeting
A multi-centric randomized phase II trial evaluating dual targeting of the EGFR with cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS metastatic colorectal cancer (UCGI 25: A UNICANCER trial).
First Author: Helene Senellart
Poster
2014 ASCO Annual Meeting
UCGI 25: A multicentric randomized phase II trial evaluating dual targeting of the epidermal growth factor (EGFR) using the combination of cetuximab and afatinib versus cetuximab alone in patients (pts) wih chemotherapy refractory wtRAS metastatic colorectal cancer (mCRC).
First Author: Hélène Senellart